About Us Our Focus Our Therapies
Our Pipeline Investors & News Careers

About Us

Learn about who we are, what we believe
and the people who lead us

Our Story Serving patient needs is our passion; delivering revolutionary treatments is our mission Our Leadership Our experienced leaders are bound by passion and science Our Values We live our values of commitment, empowerment and teamwork Our Responsibility Advancing a vision for change Medical Affairs We are committed to advancing science and medicine through awareness, education and research

Our Focus

Discover our unique scientific approach
for diseases with high unmet need.

Demodex Blepharitis Highly prevalent and damaging eyelid disease Lyme Disease A growing public health crisis with no approved solution Meibomian Gland Disease Often associated with <em>Demodex</em> infestation Rosacea A common inflammatory skin condition

Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

XDEMVY® (lotilaner ophthalmic solution) 0.25% Available to prescribe today

Our Pipeline

Explore the possibilities of our robust pipeline
to address significant unmet patient needs

Pipeline Overview A commitment to pursuing the root cause of disease TP-03 A potential candidate for meibomian gland disease TP-04 An investigational treatment for papulopustular rosacea TP-05 An investigational therapy for the prevention of Lyme disease

Investors & News

Find additional corporate
and stock information.

Investors Overview
News & Presentations
Events
Financials
PublicationsCorporate Governance
Stock Information
Other Resources

About Us

Learn about who we are, what we believe
and the people who lead us

Our StoryOur LeadershipOur ValuesOur ResponsibilityMedical Affairs

Our Focus

Discover our unique scientific approach
for diseases with high unmet need.

Demodex BlepharitisLyme DiseaseMeibomian Gland DiseaseRosacea

Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

XDEMVY® (lotilaner ophthalmic solution) 0.25%

Our Pipeline

Explore the possibilities of our robust pipeline
to address significant unmet patient needs

Pipeline OverviewTP-03TP-04TP-05

Investors & News

Find additional corporate
and stock information.

Investors Overview
News & Presentations
Events
Financials
PublicationsCorporate Governance
Stock Information
Other Resources
Careers

SEC Filing Details

Document Details

Form
8-K
Filing Date
June 18, 2024
Document Date
June 13, 2024
Form Description
Report of unscheduled material events or corporate event
Filing Group
Current Reports
Company
Tarsus Pharmaceuticals
Issuer
TARSUS PHARMACEUTICALS, INC.